publication . Other literature type . Article . 2015

Regional Gastrointestinal Transit Times in Patients With Carcinoid Diarrhea: Assessment With the Novel 3D-Transit System

Gregersen, Tine; Haase, Anne-Mette; Schlageter, Vincent; Gronbaek, Henning; Krogh, Klaus;
  • Published: 01 Jul 2015
  • Publisher: The Korean Society of Neurogastroenterology and Motility
Abstract
BACKGROUND/AIMS: The paucity of knowledge regarding gastrointestinal motility in patients with neuroendocrine tumors and carcinoid diarrhea re-stricts targeted treatment. 3D-Transit is a novel, minimally invasive, ambulatory method for description of gastrointestinal motility. The system has not yet been evaluated in any group of patients. We aimed to test the performance of 3D-Transit in patients with carcinoid diarrhea and to compare the patients' regional gastrointestinal transit times (GITT) and colonic motility patterns with those of healthy subjects. <br/>METHODS: Fifteen healthy volunteers and seven patients with neuroendocrine tumor and at least 3 bowel ...
Subjects
free text keywords: Gastroenterology, Clinical Neurology, Transit system, Library science, Medicine, business.industry, business, Data interpretation, Gastrointestinal transit, Internal medicine, medicine.medical_specialty, Endocrinology, Original Article, Capsules, Carcinoid tumor, Diarrhea, Gastrointestinal motility
35 references, page 1 of 3

Fröjd, C, Larsson, G, Lampic, C, von Essen, L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007; 5: 18 [OpenAIRE] [PubMed] [DOI]

Modlin, IM, Kidd, M, Latich, I, Zikusoka, MN, Shapiro, MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128: 1717-1751 [OpenAIRE] [PubMed] [DOI]

Spiller, R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil. 2007; 19 (suppl 2): 25-31 [OpenAIRE] [PubMed] [DOI]

Hansen, MB, Arif, F, Gregersen, H, Bruusgaard, H, Wallin, L. Effect of serotonin on small intestinal contractility in healthy volunteers. Physiol Res. 2008; 57: 63-71 [OpenAIRE] [PubMed]

Nakajima, M, Shiihara, Y, Shiba, Y. Effect of 5-hydroxytryptamine on gastrointestinal motility in conscious guinea-pigs. Neurogastroenterol Motil. 1997; 9: 205-214 [OpenAIRE] [PubMed] [DOI]

Budhoo, MR, Kellum, JM. Evidence for a 5-HT4 receptor pathway mediating chloride secretion in the rat distal colon. J Surg Res. 1994; 57: 44-48 [OpenAIRE] [PubMed] [DOI]

Lördal, M, Hellström, PM. Serotonin stimulates migrating myoelectric complex via 5-HT3-receptors dependent on cholinergic pathways in rat small intestine. Neurogastroenterol Motil. 1999; 11: 1-10 [OpenAIRE] [PubMed] [DOI]

Tack, J, Broekaert, D, Corsetti, M, Fischler, B, Janssens, J. Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. Aliment Pharmacol Ther. 2006; 23: 265-274 [OpenAIRE] [PubMed] [DOI]

Kvols, LK, Moertel, CG, O’Connell, MJ, Schutt, AJ, Rubin, J, Hahn, RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986; 315: 663-666 [OpenAIRE] [PubMed] [DOI]

Janson, ET, Oberg, K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993; 32: 225-229 [OpenAIRE] [PubMed] [DOI]

O’Toole, D, Ducreux, M, Bommelaer, G. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000; 88: 770-776 [OpenAIRE] [PubMed] [DOI]

Wolin, EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012; 5: 161-168 [OpenAIRE] [PubMed]

Janson, ET, Sorbye, H, Welin, S. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2014; 53: 1284-1297 [OpenAIRE] [PubMed] [DOI]

Rinke, A, Müller, HH, Schade-Brittinger, C. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients With metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009; 27: 4656-4663 [PubMed] [DOI]

Gregersen, T, Grønbæk, H, Worsøe, J, Schlageter, V, Laurberg, S, Krogh, K. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. Scand J Gastroenterol. 2011; 46: 895-902 [OpenAIRE] [PubMed] [DOI]

35 references, page 1 of 3
Abstract
BACKGROUND/AIMS: The paucity of knowledge regarding gastrointestinal motility in patients with neuroendocrine tumors and carcinoid diarrhea re-stricts targeted treatment. 3D-Transit is a novel, minimally invasive, ambulatory method for description of gastrointestinal motility. The system has not yet been evaluated in any group of patients. We aimed to test the performance of 3D-Transit in patients with carcinoid diarrhea and to compare the patients' regional gastrointestinal transit times (GITT) and colonic motility patterns with those of healthy subjects. <br/>METHODS: Fifteen healthy volunteers and seven patients with neuroendocrine tumor and at least 3 bowel ...
Subjects
free text keywords: Gastroenterology, Clinical Neurology, Transit system, Library science, Medicine, business.industry, business, Data interpretation, Gastrointestinal transit, Internal medicine, medicine.medical_specialty, Endocrinology, Original Article, Capsules, Carcinoid tumor, Diarrhea, Gastrointestinal motility
35 references, page 1 of 3

Fröjd, C, Larsson, G, Lampic, C, von Essen, L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007; 5: 18 [OpenAIRE] [PubMed] [DOI]

Modlin, IM, Kidd, M, Latich, I, Zikusoka, MN, Shapiro, MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128: 1717-1751 [OpenAIRE] [PubMed] [DOI]

Spiller, R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil. 2007; 19 (suppl 2): 25-31 [OpenAIRE] [PubMed] [DOI]

Hansen, MB, Arif, F, Gregersen, H, Bruusgaard, H, Wallin, L. Effect of serotonin on small intestinal contractility in healthy volunteers. Physiol Res. 2008; 57: 63-71 [OpenAIRE] [PubMed]

Nakajima, M, Shiihara, Y, Shiba, Y. Effect of 5-hydroxytryptamine on gastrointestinal motility in conscious guinea-pigs. Neurogastroenterol Motil. 1997; 9: 205-214 [OpenAIRE] [PubMed] [DOI]

Budhoo, MR, Kellum, JM. Evidence for a 5-HT4 receptor pathway mediating chloride secretion in the rat distal colon. J Surg Res. 1994; 57: 44-48 [OpenAIRE] [PubMed] [DOI]

Lördal, M, Hellström, PM. Serotonin stimulates migrating myoelectric complex via 5-HT3-receptors dependent on cholinergic pathways in rat small intestine. Neurogastroenterol Motil. 1999; 11: 1-10 [OpenAIRE] [PubMed] [DOI]

Tack, J, Broekaert, D, Corsetti, M, Fischler, B, Janssens, J. Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. Aliment Pharmacol Ther. 2006; 23: 265-274 [OpenAIRE] [PubMed] [DOI]

Kvols, LK, Moertel, CG, O’Connell, MJ, Schutt, AJ, Rubin, J, Hahn, RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986; 315: 663-666 [OpenAIRE] [PubMed] [DOI]

Janson, ET, Oberg, K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993; 32: 225-229 [OpenAIRE] [PubMed] [DOI]

O’Toole, D, Ducreux, M, Bommelaer, G. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000; 88: 770-776 [OpenAIRE] [PubMed] [DOI]

Wolin, EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012; 5: 161-168 [OpenAIRE] [PubMed]

Janson, ET, Sorbye, H, Welin, S. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2014; 53: 1284-1297 [OpenAIRE] [PubMed] [DOI]

Rinke, A, Müller, HH, Schade-Brittinger, C. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients With metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009; 27: 4656-4663 [PubMed] [DOI]

Gregersen, T, Grønbæk, H, Worsøe, J, Schlageter, V, Laurberg, S, Krogh, K. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. Scand J Gastroenterol. 2011; 46: 895-902 [OpenAIRE] [PubMed] [DOI]

35 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Other literature type . Article . 2015

Regional Gastrointestinal Transit Times in Patients With Carcinoid Diarrhea: Assessment With the Novel 3D-Transit System

Gregersen, Tine; Haase, Anne-Mette; Schlageter, Vincent; Gronbaek, Henning; Krogh, Klaus;